Jeil Pharm Market Cap ($71.68 Million)
Market Cap & Net Worth: Jeil Pharm (002620)
Jeil Pharm market cap. Jeil Pharm (KO:002620) has a market capitalization of $71.68 Million (₩105.77 Billion) as of November 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #20320 globally and #1093 in its home market, demonstrating a -2.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jeil Pharm's stock price ₩6890.00 by its total outstanding shares 15351125 (15.35 Million). Also see 002620 cash flow conversion for how efficiently the company converts equity into cash flow.
Jeil Pharm Market Cap History (2015–2026)
Jeil Pharm market cap history from 2015 to 2026. Data shows change from $269.14 Million to $71.68 Million (-6.95% CAGR). Check current stock price of Jeil Pharm for real-time trading data and today's change.
Jeil Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jeil Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 002620 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Jeil Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Jeil Pharm's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $567.49 Million | $617.28 Billion | $7.89 Billion | 0.00x | 0.07x |
| 2017 | $364.21 Million | $44.44 Billion | $518.82 Billion | 0.01x | 0.00x |
| 2018 | $263.21 Million | $142.74 Billion | $7.07 Billion | 0.00x | 0.04x |
| 2019 | $174.14 Million | $725.46 Billion | -$90.66 Billion | 0.00x | N/A |
| 2020 | $217.91 Million | $762.00 Billion | $11.43 Billion | 0.00x | 0.02x |
| 2021 | $165.11 Million | $762.57 Billion | -$3.48 Billion | 0.00x | N/A |
| 2022 | $159.53 Million | $792.96 Billion | -$74.56 Billion | 0.00x | N/A |
| 2023 | $122.45 Million | $804.04 Billion | -$16.25 Billion | 0.00x | N/A |
| 2024 | $81.35 Million | $779.82 Billion | -$51.16 Billion | 0.00x | N/A |
| 2025 | $83.64 Million | $657.61 Billion | $14.64 Billion | 0.00x | 0.01x |
Competitor Companies of 002620 by Market Capitalization
Companies near Jeil Pharm in the global market cap rankings as of November 4, 2026. Also see how large is Jeil Pharm's balance sheet for a full breakdown of the balance sheet.
Key companies related to Jeil Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Jeil Pharm (2015–2026)
Market capitalization of Jeil Pharm from 2015 to today. Between 2015 and today, Jeil Pharm's market cap moved from $269.14 Million to $ 71.68 Million, with a yearly change of -6.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩71.68 Million | -14.30% |
| 2025 | ₩83.64 Million | +2.81% |
| 2024 | ₩81.35 Million | -33.56% |
| 2023 | ₩122.45 Million | -23.24% |
| 2022 | ₩159.53 Million | -3.38% |
| 2021 | ₩165.11 Million | -24.23% |
| 2020 | ₩217.91 Million | +25.13% |
| 2019 | ₩174.14 Million | -33.84% |
| 2018 | ₩263.21 Million | -27.73% |
| 2017 | ₩364.21 Million | -35.82% |
| 2016 | ₩567.49 Million | +110.85% |
| 2015 | ₩269.14 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Jeil Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.68 Million USD |
| MoneyControl | $71.68 Million USD |
| MarketWatch | $71.68 Million USD |
| marketcap.company | $71.68 Million USD |
| Reuters | $71.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more